Senior Medical Director, Kidney Disease, Early Clinical Development CVRM

Company: AstraZeneca
Location: Montgomery Village
Posted on: January 10, 2026

Job Description:

The Senior Medical Director will be focused on Kidney Disease and related conditions that impact kidney function. In this role, you will have the opportunity to work at the forefront of early clinical and translational research within CVRM. In a multidisciplinary environment, you will play a key role in progressing a rich and diverse pipeline of both small and large molecules in numerous active clinical programs. Who We Are In the Cardiovascular, Renal & Metabolism (CVRM)Translational Medicine & Clinical Development (TSCD) department, we are investigating the underlying factors contributing to CVRM disease progressionusing advanced scientific methodologies and data-driven drug discovery. In this context, we are evaluating a wide range of different drug modalities from our rich CVRM portfolio of compoundsacross kidney diseasepatient populations. TSCD is where science meets clinical drug development with a focus upon delivering innovative, early phase clinical studies and accelerating human target validation while collaborating closely with our late phase clinical development and regulatory colleagues who guide our pivotal phase 3 clinical studies. What You Will Do You will be responsible for managing and leading to early phase I-II global clinical trialsand related clinical research projects for compounds that are targeting kidney disease, as well as serving as an expert on the design, conduct, monitoring, data interpretation, and reporting of these studies. Additionally, you will work on cross-functional teams within our TSCD group and across the broader globalCVRM organization that are framing our strategies and development plans for compounds that are targeting cardiovascular diseases such asHeart Failure,as well as major metabolic disorders, such as Type 2 Diabetes, Obesity, and Metabolic Dysfunction-Associated Steatohepatitis, given that these disorders intersect with chronic kidney disease and influence disease progression. Responsibilities include: Lead early Phase I–II global trials in kidneydisease: clinical strategy, protocol design, studyconduct, monitoring, data interpretation, and reporting, ensuringscientificintegrity, patient safety, and regulatorycompliance. Provide clinical leadership to cross-functional teams; integratepreclinicalinsights (targetselection, pharmacology, in vivo/in vitro data) into early clinical plans and seamless transitions to late phasedevelopment. Contribute to regulatoryinteractions and documentation (e.g., CTAs, INDs, safetyupdates, annualreports). Advance the development and validation of nonclinical and surrogateendpoints (includingimaging and biomarkers). Represent TSCD internally and externallythrough presentations, publications, and scientific forums; engagewithexternal experts and translate insightsintostrategy and study design. Helpevolvetrial operations and site engagement to improve speed, quality, and inclusivity in early studies. Collaborateacross CVRM on programs in heartfailure, type 2 diabetes, obesity, and metabolicdysfunction-associatedsteatohepatitis, given theirintersectionwithkidneydisease. Basic Qualifications: MD, MBBS or MD/PhD withestablishedclinical or research expertise in in the treatment of kidney diseases. Minimum of 5 years of clinical research in academia and/or the pharmaceutical/biotechnologyindustry. Experience designing, executing, monitoring, interpreting, and overseeingsafety in early clinical and translationaltrials preferred. Strong command of biomarkers, surrogateendpoints, and biostatistics, supported by a robust publication record. Welldeveloped interpersonal skills, effective teamwork, and the ability to engagestakeholderseffectivelyacrossfunctions, geographies, and disciplines. Why AstraZeneca? Here, we need leadership at every level – Physicians who not only have clinical and scientific expertise, but also the ability to build a case, engage multiple partners, and communicate effectively with different audiences. With that kind of remit comes great responsibility. We truly believe that everyone contributes with an outstanding set of competence. Your curiosity and passion for personal development combined with support from colleagues, mentors and leaders, will ensure you maximize your skills, abilities and contribution. The annual base pay for this position ranges from $280,895 – $421,342 USD. Hourly and salaried non-exempt employees will also be paid overtime pay when working qualifying overtime hours. Base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience. In addition, our positions offer a short-term incentive bonus opportunity; eligibility to participate in our equity-based long-term incentive program. Benefits offered included a qualified retirement program [401(k) plan]; paid vacation and holidays; paid leaves; and, health benefits including medical, prescription drug, dental, and vision coverage in accordance with the terms and conditions of the applicable plans. Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base pay (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors. When we put unexpected teams in the same room, we unleash bold thinking with the power to inspire life-changing medicines. In-person working gives us the platform we need to connect, work at pace and challenge perceptions. Thats why we work, on average, a minimum of three days per week from the office. But that doesnt mean were not flexible. We balance the expectation of being in the office while respecting individual flexibility.

Keywords: AstraZeneca, Wilmington , Senior Medical Director, Kidney Disease, Early Clinical Development CVRM, Science, Research & Development , Montgomery Village, Delaware